A Study Investigating the Pharmacokinetics of FV-100 With and Without Ritonavir in Healthy Volunteers

Inclusion criteria

• Capable of giving written informed consent
• Non-tobacco user for at least 3 months prior to selection
• Healthy on the basis of physical examination, medical history, ECG and clinical laboratory testing at screening

Exclusion criteria

(must NOT meet the following)

• Infected with Hepatitis A, B, C, or HIV
• History of or any current medical condition which could impact safety of the participant
• A positive urine drug test
• Consumption of more than 2 units of alcoholic beverages per day or more than 14 per week
• Received an investigational drug or vaccine or used an investigational medical device within 3 months or 5 half-lives before the planned start of treatment or prior treatment with FV-100
• Subjects who have used any drugs or substances known to inhibit or induce cytochrome(CYP) P450 enzymes and/or P-gp within 28 days prior to the first dose and throughout study
• Subjects who have, within 2 weeks prior to the first dose of study drug, ingested grapefruit or grapefruit juice, apple or orange juice, vegetables from the mustard green family or charbroiled meats